XTL Biopharmaceuticals

Treatments for Autoimmune Diseases

Health Tech & Life Sciences
Public on TASE on Sep 2000
Public on NASDAQ on Sep 2005

Company Overview

Snapshot

Founded in March 1993, XTL Biopharmaceuticals operates with 1–10 employees. The company has raised $30.04M across 6 funding rounds from 8 investors. In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air, marking its entry into the autism market.

Business overview

XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates to address unmet clinical needs. The company's pipeline includes hCDR1 peptide for systemic lupus erythematosus (SLE), recombinant erythropoietin for advanced-stage multiple myeloma patients, and SAM-101 for psychotic diseases, particularly schizophrenia. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, XTL serves the pharmaceutical market with its biological-based therapies.

Strategic signal

In May 2026, XTL Biopharmaceuticals announced the receipt of a Staff Delist Determination from Nasdaq, indicating significant challenges regarding its listing status. This development signals potential instability and a critical juncture for the company's public market presence, requiring strategic action to maintain its listing.

Company Intelligence Q&A

What was a key strategic acquisition made by XTL Biopharmaceuticals in early 2026?
In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air. This acquisition marked XTL's entry into the autism market.
What recent notification did XTL Biopharmaceuticals receive from Nasdaq?
In May 2026, XTL Biopharmaceuticals announced the receipt of a Staff Delist Determination from Nasdaq. This followed an earlier notification in February 2026 regarding a minimum bid price deficiency and plans to request a hearing.
What was XTL Biopharmaceuticals' total capital raised?
XTL Biopharmaceuticals has raised a total of $30.04M across 6 funding rounds.
What was XTL Biopharmaceuticals' most recent acquisition prior to 2026?
In August 2024, XTL Biopharmaceuticals completed the acquisition of The Social Proxy and a private placement of $1.5 million.
When did XTL Biopharmaceuticals become publicly traded?
XTL Biopharmaceuticals went public on the TASE in September 2000 and subsequently on NASDAQ in September 2005.

External links